Page 5 - Apr 27
P. 5

Members' Communications


        Anniversaries

        Andrew & Julianne LEHMANN (2 /5 )

        Rotary Information

        Novel oral polio vaccine type 2 by India's Biological E achieves WHO prequalification

        12  February  2026  -  The  Global  Polio  Eradication  Initiative  (GPEI)  welcomes  the
        World Health Organization (WHO)'s decision to grant prequalification (PQ) status to the
        novel oral polio vaccine type 2 (nOPV2) by India's Biological E. Limited (BE). Since
        March 2024, BE has added 700 million doses of nOPV2 into the global stockpile.
        With this new PQ, BE becomes the second full manufacturer of nOPV2, joining PTB
        in  Indonesia.  Together,  the  two  manufacturers  provide  diversified,  stable  global
        production capacity for this critical tool to stop outbreaks of type 2 variant poliovirus
        for good.

        With the new WHO recommendation, BE is expected to produce 600 million doses per
        year,  strengthening  global  outbreak  response  capacity  and  ensuring  countries  can
        access nOPV2 rapidly when needed.

        "Expanding  nOPV2  manufacturing  is  essential  to  ensuring  countries  can  respond
        quickly  to  variant  poliovirus  outbreaks,"  said  Mike  McGovern,  Chair  of  the
        International  PolioPlus  Committee,  Rotary  International  and  Chair  of  the  Polio
        Oversight Board, GPEI. "Biological E's prequalification status strengthens the global
        supply and brings us closer to ending these outbreaks for good."

        More than 2 billion doses of nOPV2 have already been administered worldwide since
        they were first introduced in 2021. After years of large-scale use, evidence shows that
        nOPV2  is  effective  in  stopping  variant  poliovirus  outbreaks.  Estimated  risk  of  new
        variant  polio  outbreaks  is  nearly  80%  lower  than  what  would  be  expected  if
        monovalent oral poliovirus vaccine type 2 was used at the same scale. This improved
        stability  makes  nOPV2  a  critical  asset  in  the  global  effort  to  eliminate  variant
        polioviruses,  complementing  rapid,  high-quality  immunization  campaigns  and  strong
        disease surveillance systems.

        World Immunisation Week 24-30 April 2026


        World  Immunization  Week  is  quickly  approaching  and  Rotary  and  our  partners
        commemorate World Immunization Week, 24-30 April every year, to raise awareness of the
        importance of vaccination and highlight the success of our polio eradication efforts.

        The progress that Rotary and our partners have made toward eradicating polio is a success
        story  that  is  important  to  tell,  especially  during  this  final  effort  to  reach  our  goal.  Our
        members are our greatest advocates and supporters, and we need your help more than ever to
        share our story with your communities.
   1   2   3   4   5   6   7   8   9   10